Print this article
- 10/17/2023

Cerbios-Pharma SA expanded capacity for ADCs

Chimica Oggi-Chemistry Today

During its 50 years history, Cerbios-Pharma SA always invested in expanding its capabilities. In May 2023 a new CGMP suite dedicated to the manufacturing of clinical and commercial cytotoxic linker-payloads (OEL <10 ng/m3) for ADCs obtained the approval of Swissmedic. 


Cerbios-Pharma SA, a pharmaceutical company headquartered in Lugano, Switzerland, with almost 50 years of experience in the pharmaceutical industry, is a frontrunner in CDMO services for HPAPIs and ADCs.  

The most recent milestone consists in the approval by Swissmedic of the new facility in Lugano site dedicated to the manufacturing of clinical and commercial HPAPIs including cytotoxic linker-payloads for ADCs.  

The plant is located in a brand-new building and features two cGMP manufacturing lines equipped with state-of-the-art isolator containment technology to handle highly potent molecules up to OEL <10 ng/m3. 

The facility has been designed to meet the current market needs in Oncology and, more specifically, ADC space where molecules require technologies such as high- and low-pressure chromatography, nanofiltration and freeze drying. Build to host dedicated and single use reactors up to 100 L, the line’s adaptable capacity will handle batches from grams up kg scale covering clinical and commercial stages.  

The regulatory authorization marks the latest step in Cerbios’ recent campaign of investment in expansion of its advanced contract development and manufacturing (CDMO) services promoted through its Proveo™ division, the one stop shop for ADCs manufacturing. 

Cerbios-Pharma SA Chief Commercial Officer Denis Angioletti commented: “This new building is a result of our long-term strategy in growing in a sustainable manner, with the commitment to provide high quality CMO services, advanced technologies and strong know-how for our valued customers, consolidating our position as one of the leading companies in the highly potent and cytotoxic molecules space for ADCs and not only.” 

In perspective of a new expansion, Cerbios recently also bought a neighboring land: the target is to double the company bioconjugation capacity for ADCs by investing in a new hub to reinforce Cerbios’ commitment to provide best-in-class services for partners worldwide. 

Cerbios-Pharma SA will be present from the 24th to the 26th of October at CPHI Barcelona (Booth 4G50) with its CDMO services for HPAPIs and ADCs and additionally its extensive portfolio including generic APIs, finished dosages based on SF68® proprietary probiotic strain.